We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials.
1. What are the unmet needs in the management of patients with treatment-resistant chronic-phase chronic myeloid leukemia? 00:11-00:40
2. Could you tell us a little about ponatinib and the clinical evidence supporting its use in this treatment setting? 00:40-01:24
3. What were the objectives of the analysis of data from the PACE and OPTIC trials? 01:24-02:36
4. What were the efficacy findings from the dose reduction strategies of the two studies? 02:38-03:48
5. What are the clinical implications of these findings and what further research is needed? 03:48-04:30
Speaker Disclosure: Elias Jabbour has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
Share this Video
Related Videos In Leukaemia
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]
Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]